La chaîne d'options affiche les données clés des options sur actions de Aquestive Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Aquestive Therapeutics..

Aquestive Therapeutics (NASDAQ:AQST) Stock, Chaîne d'Options

Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics Inc

Keybanc analyst Arvind Ramnani upgrades Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) from Sector Weight to Overweight and announces $126 price target.

News

Upgrades

Price Target

Analyst Ratings

QTWO

Keybanc Upgrades Q2 Holdings to Overweight, Announces $126 Price Target

Key preclinical milestone for novel, non-opioid extended-release pain therapeutic&nbsp;&nbsp;

SILO

Silo Pharma Launches Pharmacokinetic Study For SP-26, Targeting Non-Opioid Chronic Pain Treatment

AMST

Amesite Disclosed Nursemagic Enterprise Contract Wins In High Growth Companies With Hundreds Of Franchise Owners Across The Country

AGEN

Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Earnings

TKLF

CORRECTION: Tokyo Lifestyle Co H1 EPS $0.03 Down From $0.05 YoY, Sales $98.00M Up From $74.16M YoY

Draganfly's medical drone delivery infrastructure offers new model for future improvement in service time for Home Hospital care

DPRO

Draganfly Successfully Conducts Proof-Of-Concept Flights For Medical Drone Delivery With Mass General Brigham

Raymond James analyst Joseph Yanchunis initiates coverage on FinWise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FINW#NASDAQ">FINW</a>) with a Outperform rating and announces Price Target of $21.

Initiation

FINW

Raymond James Initiates Coverage On FinWise with Outperform Rating, Announces Price Target of $21

MESO

Mesoblast Announced Its Upcoming Addition To The Nasdaq Biotechnology Index As Part Of The Annual Reconstitution Of The 2024 Nasdaq Index

No dose-limiting toxicities were observed in the RAMP 203 first triplet combination cohort of avutometinib and LUMAKRAS&#x2122; (sotorasib) plus defactinib in patients previously treated with a G12C inhibitor

VSTM

Verastem Reports RAMP 203 Data: No Dose-Limiting Toxicities In Triplet Therapy For KRAS G12C NSCLC

Trading in the common shares and other listed securities of the Company on the Toronto Stock Exchange ("TSX") and the New York Stock Exchange (the "NYSE") has been halted.

Lion Electric Intends To Seek Recognition Of CCAA Proceedings In US Under Chapter 15 Of Bankruptcy Code; Files Application For Creditor Protection Under CCAA

WIIM

General Mills shares are trading lower after the company reported Q2 financial results and lowered FY25 adjusted EPS outlook.

CRVS

Corvus Pharmaceuticals Announced Interim Data From The Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Trial Evaluating Soquelitinib In Patients With Moderate To Severe Atopic Dermatitis

Raymond James analyst Andrew Marok initiates coverage on DoubleVerify Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Outperform rating and announces Price Target of $25.

Raymond James Initiates Coverage On DoubleVerify Hldgs with Outperform Rating, Announces Price Target of $25

STRM

Streamline Health Solutions Announced That It Has Signed A New Contract For The Use Of RevID With A 400-bed, Oracle Health-EHR Based Health System With Facilities In Western Texas

Offerings

PESI

Perma-Fix Environmental Services Prices Public Offering Of 2.20M Shares Of Its Common Stock At $10.00 Per Share

Piper Sandler analyst John Barnidge upgrades Principal Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) from Neutral to Overweight and maintains the price target from $90 to $90.

Piper Sandler Upgrades Principal Finl Gr to Overweight, Maintains Price Target to $90

Jefferies analyst Yaron Kinar downgrades RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) from Buy to Hold and lowers the price target from $304 to $282.

Downgrades

Jefferies Downgrades RenaissanceRe Holdings to Hold, Lowers Price Target to $282

General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.22 by 14.75 percent. This is a 12 percent increase over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $5.24 billion which beat the analyst consensus estimate of $5.14 billion by 1.94 percent. This is a 1.97 percent increase over sales of $5.14 billion the same period last year.

Earnings Beats

CORRECTION: General Mills Q2 2025 Adj EPS $1.40 Beats $1.22 Estimate, Sales $5.24B Beat $5.14B Estimate

PLRZ: 282% &#x7C; <a href="https://www.benzinga.com//node/42549301">Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025</a>
&nbsp;
CRVS: 24% &#x7C; <a href="https://www.benzinga.com//node/42540476">Corvus Pharmaceuticals shares are trading higher after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.</a>
&nbsp;
OKLO: 10% &#x7C; <a href="https://www.benzinga.com//node/42550029">Oklo And Switch Partner To Deploy 12 GW Of Advanced Nuclear Power</a>

Movers

Trading Ideas

OKLO

PLRZ

Market-Moving News for December 18th

Janney Montgomery Scott analyst Robert Stevenson initiates coverage on Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) with a Buy rating.

STRW

Janney Montgomery Scott Initiates Coverage On Strawberry Fields REIT with Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a price target of $1...

Promising Future and Strategic Advancements: Buy Recommendation for Aquestive Therapeutics

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics +

Aquestive Therapeutics (AQST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

Positive Developments and Strategic Partnerships Justify Buy Rating for Aquestive Therapeutics

Franklin Biotechnology Discovery Fund Q3 2024 Commentary

ARS Pharmaceuticals: Demand Curve Is Key Unknown

The latest update is out from Aquestive Therapeutics ( ($AQST) ). Aquestive Therapeutics, Inc. has received positive feedback from the FDA regardin...

Aquestive Therapeutics Gains FDA Support for Anaphylm

Lake Street analyst Thomas Flaten maintained a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a price target of $10.00...

Aquestive Therapeutics (AQST) Receives a Buy from Lake Street

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report), with a pri...

Aquestive Therapeutics: Promising FDA Feedback and Solid Foundation Support Buy Rating

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on AQST stock, giving a Buy rating on December 2. Roanna Ruiz has given he...

Buy Rating Affirmed for Aquestive Therapeutics Amid Positive FDA Feedback and Strategic Progress on Anaphylm

Cantor Fitzgerald initiated coverage of Aquestive Therapeutics (AQST) with an Overweight rating and $17 price target Th company's "secret sauce" is...

Aquestive Therapeutics initiated with an Overweight at Cantor Fitzgerald

AAPL

ALNY

APGE

APLT

AQST

ASMIY

ASMXF

AXNX

BNTC

BORR

CNTA

GILD

GSAT

HLVX

HRTX

IWGFF

MRNA

MRUS

NBIX

NPICF

NPIFF

PCVX

PRAX

PTCT

RVNC

SPRY

WEWKQ

WEWOQ

WLKP

XMTR

Health Care

Press Releases

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

General

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Comments

Aquestive Therapeutics

Aquestive Therapeutics (AQST) Options

Aquestive Therapeutics (NASDAQ:AQST) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL